SR1062LRB101 20922 MST 70876 r

1
SENATE RESOLUTION

 
2    WHEREAS, Many peoples with serious, chronic mental
3illness, such as schizophrenia and other schizoaffective
4disorders, bipolar disorder, or severe depression, require
5treatment with medications that work as dopamine receptor
6blocking agents (DRBAs), including antipsychotics; and
 
7    WHEREAS, While ongoing treatment with these medications
8can be very helpful and even lifesaving for many people, it can
9also lead to Tardive Dyskinesia (TD); and
 
10    WHEREAS, Many people who have gastrointestinal disorders,
11including gastroparesis, nausea, and vomiting, also require
12treatment with DRBAs; and
 
13    WHEREAS, Treatment of gastrointestinal disorders with
14DRBAs can be very helpful, but for many patients, it can lead
15to Tardive Dyskinesia; and
 
16    WHEREAS, Tardive Dyskinesia is a movement disorder that is
17characterized by random, involuntary, and uncontrolled
18movements of different muscles in the face, trunk, and
19extremities; in some cases, people may experience movement of
20the arms, legs, fingers, and toes; it may affect the tongue,
21lips, and jaw; symptoms may include swaying movements of the

 

 

SR1062- 2 -LRB101 20922 MST 70876 r

1trunk or hips and may impact the muscles associated with
2walking, speech, eating, and breathing; and
 
3    WHEREAS, Tardive Dyskinesia can develop months, years, or
4decades after a person starts taking DRBAs and even after they
5have discontinued use of those medications; not everyone who
6takes a DRBA develops TD, but if it develops, it is often
7permanent; and
 
8    WHEREAS, Common risk factors for Tardive Dyskinesia
9include advanced age and alcoholism or other substance abuse
10disorders; postmenopausal women and people with a mood disorder
11are also at a higher risk of developing Tardive Dyskinesia; and
 
12    WHEREAS, A person is at a higher risk for TD after talking
13DRBAs for three months or longer, but the longer the person is
14on these medications then the higher the risk of developing
15Tardive Dyskinesia; and
 
16    WHEREAS, Studies suggest that overall risk of developing
17Tardive Dyskinesia is between 10 and 30 percent; and
 
18    WHEREAS, It is estimated that over 500,000 Americans suffer
19from Tardive Dyskinesia; according to the National Alliance for
20Mental Illness, one in every four patients receiving long-term
21treatment with an antipsychotic medication will experience

 

 

SR1062- 3 -LRB101 20922 MST 70876 r

1Tardive Dyskinesia; and
 
2    WHEREAS, Years of difficult and challenging research have
3resulted in recent scientific breakthroughs, with two new
4treatments for Tardive Dyskinesia approved by the United States
5Food and Drug Administration; and
 
6    WHEREAS, Tardive Dyskinesia is often unrecognized, and
7patients suffering from the illness are commonly misdiagnosed;
8regular screening for TD in patients taking DRBA medications is
9recommended by the American Psychiatric Association (APA); and
 
10    WHEREAS, Patients suffering from Tardive Dyskinesia often
11suffer embarrassment due to abnormal and involuntary
12movements, which leads them to withdraw from society and
13increasingly isolate themselves as the disease progresses; and
 
14    WHEREAS, Caregivers of patients with Tardive Dyskinesia
15face many challenges and are often responsible for the overall
16care of the TD patient; therefore, be it
 
17    RESOLVED, BY THE SENATE OF THE ONE HUNDRED FIRST GENERAL
18ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 3-9,
192020 as "Tardive Dyskinesia Awareness Week" in the State of
20Illinois; and be it further
 

 

 

SR1062- 4 -LRB101 20922 MST 70876 r

1    RESOLVED, That we urge the citizens of Illinois and those
2across the country to become better informed about Tardive
3Dyskinesia.